Singapore markets close in 1 hour 34 minutes

Natera, Inc. (NTRA)

NasdaqGS - NasdaqGS Real-time price. Currency in USD
Add to watchlist
76.16+1.97 (+2.66%)
At close: 04:00PM EST
76.92 +0.76 (+1.00%)
After hours: 08:00PM EST
Full screen
Loading interactive chart…
  • Insider Monkey

    Natera (NTRA) Management Increased Full Year Guidance

    Fred Alger Management, an investment management company, released its “Alger Weatherbie Specialized Growth Fund” fourth quarter 2023 investor letter. A copy of the same can be downloaded here. US markets rallied strongly in Q4, with the S&P Index up 11.69%. However, Class A shares of the fund underperformed the Russell 2500 Growth Index. Healthcare and IT […]

  • Business Wire

    Natera Announces Next Phase of CareDx Patent Infringement Litigation Seeking Royalty For All Ongoing And Future AlloSure Tests

    AUSTIN, Texas, February 27, 2024--Natera, Inc. (NASDAQ: NTRA), a global leader in cell-free DNA testing, today announced the next phase of proceedings in its patent infringement litigation against CareDx. The U.S. District Court for the District of Delaware will now determine if CareDx owes a royalty for future infringement related to ongoing and future AlloSure testing occurring after August 2023.

  • Business Wire

    Medicare Extends Coverage of Natera’s Signatera™ MRD Test to Ovarian Cancer and Neoadjuvant Breast Cancer

    AUSTIN, Texas, February 26, 2024--Natera, Inc. (NASDAQ: NTRA), a global leader in cell-free DNA testing, today announced that its personalized and tumor-informed molecular residual disease (MRD) test, Signatera, has met coverage requirements from the Centers for Medicare & Medicaid Services’ (CMS) Molecular Diagnostics Services Program (MolDX) in two new indications: ovarian cancer in the adjuvant and surveillance settings, and breast cancer in the neoadjuvant setting.